Condition
Parathyroid Gland Carcinoma
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02834013Phase 2Active Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03039439Recruiting
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
NCT06645951RecruitingPrimary
Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma
Showing all 3 trials